Quarterly ResultJul 30, 2026, 07:41 AM
Wave Life Sciences Q2 Net Loss $69.4M; Cash Runway into 3Q 2028
AI Summary
Wave Life Sciences Ltd. reported its second quarter 2026 financial results, with cash, cash equivalents, and marketable securities of $490.6 million as of June 30, 2026, providing a cash runway into Q3 2028. The company posted a net loss of $69.4 million on revenues of $2.3 million for the quarter. Alongside the financial update, Wave Life Sciences provided significant business updates, including the initiation of dosing in the Phase 2a INLIGHT trial for WVE-007 in obesity and a scheduled FDA meeting for WVE-006's potential accelerated approval pathway.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $490.6 million as of June 30, 2026.
- Company expects current cash runway to extend into the third quarter of 2028.
- Revenue for Q2 2026 was $2.3 million, down from $8.7 million in Q2 2025.
- Net loss for Q2 2026 increased to $69.4 million from $50.5 million in Q2 2025.
- Net loss per share was $(0.34) for Q2 2026, compared to $(0.31) in Q2 2025.
- Dosing is underway in Phase 2a of the INLIGHT trial for WVE-007 in obesity.
- FDA meeting scheduled for end of summer 2026 regarding accelerated approval pathway for WVE-006.
- CTA submission for WVE-008 for PNPLA3 liver disease is on track for 2H 2026.
Price Impact
More from WVE